{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:23:20Z","timestamp":1793064200680,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"L'hema"},{"name":"Sodebo"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-6080-8","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T11:03:21Z","timestamp":1567076601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma"],"prefix":"10.1186","volume":"19","author":[{"given":"Lina","family":"Benaniba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Tessoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Trudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Pellat-Deceunynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Amiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Minvielle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Antoine","family":"Gourraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"de Visme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Maisonneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0275-2575","authenticated-orcid":false,"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"issue":"suppl_4","key":"6080_CR1","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(suppl_4):iv52\u201361.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"6080_CR2","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6080_CR3","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516\u201320.","journal-title":"Blood."},{"key":"6080_CR4","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.14694\/EdBook_AM.2015.35.e504","volume":"35","author":"Philippe Moreau","year":"2015","unstructured":"Moreau P, Touzeau C. Multiple myeloma: from front-line to relapsed therapies. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Meet. 2015:e504\u201311.","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"6080_CR5","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/leu.2017.60","volume":"31","author":"C Touzeau","year":"2017","unstructured":"Touzeau C, Moreau P, Dumontet C. Monoclonal antibody therapy in multiple myeloma. Leukemia. 2017;31:1039\u201347.","journal-title":"Leukemia."},{"key":"6080_CR6","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726\u201337.","journal-title":"N Engl J Med"},{"key":"6080_CR7","doi-asserted-by":"crossref","unstructured":"Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017.","DOI":"10.1038\/leu.2017.138"},{"key":"6080_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883\u201392.","journal-title":"N Engl J Med"},{"key":"6080_CR9","doi-asserted-by":"crossref","unstructured":"Fonseca R, Hinkel J. Value and cost of myeloma therapy-we can afford it. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet. 2018:647\u201355.","DOI":"10.1200\/EDBK_200869"},{"key":"6080_CR10","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1038\/bcj.2015.29","volume":"5","author":"P Allart-Vorelli","year":"2015","unstructured":"Allart-Vorelli P, Porro B, Baguet F, Michel A, Cousson-G\u00e9lie F. Haematological cancer and quality of life: a systematic literature review. Blood Cancer J. 2015;5:e305.","journal-title":"Blood Cancer J"},{"key":"6080_CR11","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"6080_CR12","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","volume":"25","author":"JE Ware","year":"2000","unstructured":"Ware JE. SF-36 health survey update. Spine. 2000;25:3130\u20139.","journal-title":"Spine."},{"key":"6080_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group, EuroQol--a new facility for the measurement of health-related quality of life. Health Policy Amst Neth. 1990;16:199\u2013208.","journal-title":"Health Policy Amst Neth"},{"key":"6080_CR14","doi-asserted-by":"crossref","unstructured":"Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood. 2017.","DOI":"10.1182\/blood-2017-06-788786"},{"key":"6080_CR15","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1182\/blood-2014-01-548800","volume":"124","author":"B Tessoulin","year":"2014","unstructured":"Tessoulin B, Descamps G, Moreau P, Ma\u00efga S, Lod\u00e9 L, Godon C, et al. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH\/ROS balance. Blood. 2014;124:1626\u201336.","journal-title":"Blood."},{"key":"6080_CR16","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.cell.2015.05.002","volume":"161","author":"EZ Macosko","year":"2015","unstructured":"Macosko EZ, Basu A, Satija R, Nemesh J, Shekhar K, Goldman M, et al. Highly parallel genome-wide expression profiling of individual cells using Nanoliter droplets. Cell. 2015;161:1202\u201314.","journal-title":"Cell."},{"key":"6080_CR17","doi-asserted-by":"crossref","unstructured":"Gomez-Bougie P, Maiga S, Tessoulin B, Bourcier J, Bonnet A, Rodriguez MS, et al. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. Blood. 2018.","DOI":"10.1182\/blood-2018-03-836718"},{"key":"6080_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/leu.2015.184","volume":"30","author":"C Touzeau","year":"2016","unstructured":"Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN, Le Gouill S, et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016;30:761\u20134.","journal-title":"Leukemia."},{"key":"6080_CR19","doi-asserted-by":"publisher","unstructured":"Hanf M, Chiron D, de Visme S, Touzeau C, Maisonneuve H, Jardel H, et al. The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma. BMC Cancer. 2016;16. \n                    https:\/\/doi.org\/10.1186\/s12885-016-2844-6\n                    \n                  .","DOI":"10.1186\/s12885-016-2844-6"},{"key":"6080_CR20","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol."},{"key":"6080_CR21","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hec.1608","volume":"19","author":"NJ Devlin","year":"2010","unstructured":"Devlin NJ, Parkin D, Browne J. Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data. Health Econ. 2010;19:886\u2013905.","journal-title":"Health Econ"},{"key":"6080_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i07","volume":"45","author":"J Honaker","year":"2011","unstructured":"Honaker J, King G, Blackwell M, Amelia II. A program for missing data. J Stat Softw. 2011;45:1\u201347.","journal-title":"J Stat Softw"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6080-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6080-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6080-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T23:18:16Z","timestamp":1598570296000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6080-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6080"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6080-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,29]]},"assertion":[{"value":"6 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Each patient gives his written consent before inclusion in the study. The ethic committee Comit\u00e9 de Protection des Personnes - Tours - R\u00e9gion Centre - Ouest 1 gave its agreement to the study on July 31 2018 (2018\u2009T3\u201311 (RC18_0197) (2018-A01578\u201347) (18.07.03.46219). All participating patients gave signed informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare to have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"855"}}